CLICK HERE TO REGISTER OR LEARN MORE
Live Webinar + On-Demand Course Access
Overview
Navigating the balance between protecting innovation and ensuring access to affordable medications is crucial.
Join Jason A. Lief of Windels Marx and William C. Baton of Saul Ewing LLP in this CLE webcast as they delve into the intricacies of the Hatch-Waxman Act and its profound impact on the pharmaceutical industry. Designed for legal professionals, pharmaceutical executives, and anyone navigating the complex landscape of drug development, this webinar will provide invaluable insights into leveraging Hatch-Waxman strategies to safeguard intellectual property while ensuring broader access to life-saving medications.
Key Topics to Be Discussed
- Pleading Standards in a Hatch-Waxman Case
- How are Courts Applying Iqbal-Twombly to Hatch-Waxman Cases
- Interplay of Invalidity in PTAB IPR Proceedings and the Federal Courts
- Schrodinger’s Patents: Can a Patent be Valid and Invalid at the Same Time?
- Skinny Label Updates
- What Has Happened Since Glaxo v. Teva: Amarin v. Hikma in the Federal Circuit
- New Jersey’s Contentions Rules and How They Differ in Hatch-Waxman Cases
- Disputes Regarding Expert Reports and Contentions in New Jersey Hatch-Waxman Cases
- Early Limiting of Patent Claims in New Jersey Hatch-Waxman Cases?